US EditionPublished • loading... • Updated
CEPI Recognizes USU-Developed mAb Against Nipah Virus as a Top Innovation for Force Health Protection
Summary by DVIDS
This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.1 Articles
1 Articles
CEPI Recognizes USU-Developed mAb Against Nipah Virus as a Top Innovation for Force Health Protection
The USU-developed monoclonal antibody 1F5 (MBP1F5) has been recognized by the Coalition for Epidemic Preparedness Innovations (CEPI) as a top innovation for 2024 due to its potential to protect against the deadly Nipah virus, driving forward clinical trials.
Coverage Details
Total News Sources1
Leaning Left0Leaning Right0Center0Last UpdatedBias DistributionNo sources with tracked biases.
Bias Distribution
- There is no tracked Bias information for the sources covering this story.
Factuality
To view factuality data please Upgrade to Premium
